Nine-Year Battle to Complete Remission: A Relapsed/Refractory Follicular Lymphoma Patient’s Journey to New Life
Mr. Yang, a 49-year-old patient from Beijing, suffered from follicular lymphoma. Over the years following his diagnosis, he underwent multiple rounds of chemotherapy, targeted therapy, bispecific antibody therapy, CAR-T therapy, and various clinical trials; despite these efforts, he endured a grueling, nine-year battle against the disease, marked by a fluctuating condition, repeated relapses, and severe pulmonary complications. After treatments from various sources yielded limited results and his physical condition continued to deteriorate, Mr. Yang was referred to the Department of Lymphoma and Myeloma at Beijing Gaobo Hospital. There, through a regimen of systematic care and a novel CAR-T clinical trial, he ultimately achieved complete remission of tumors throughout his body, successfully concluding his arduous nine-year struggle.
01 Sudden Diagnosis: First-Round Treatment Plagued by Relapse
Mr. Yang developed swollen neck lymph nodes without any apparent trigger. Medical examinations, including a CT scan, revealed abnormal lymph node enlargement throughout his body; subsequent pathological testing confirmed a diagnosis of Grade 3b follicular lymphoma. Upon receiving this sudden diagnosis of a malignant tumor, he was devastated and struggled to come to terms with his illness.
Immediately following the diagnosis, Mr. Yang began a standardized treatment regimen, completing eight cycles of R-CHOP chemotherapy. While he tolerated the initial rounds reasonably well and saw significant early results, he failed to achieve complete clinical remission and had to rely on targeted therapy to maintain disease stability. Regrettably, the lymph node masses recurred just three months after treatment ended; this relapse dealt a severe psychological blow. However, with the encouragement and support of his family, Mr. Yang quickly regained his composure, actively sought new treatment options, and remained committed to fighting the cancer.
02 Nine Years of Seeking Treatment: Relapses and Severe Complications
Over the nine years following his diagnosis, Mr. Yang sought care at various hospitals in Beijing and exhausted all mainstream anti-tumor treatments, including chemotherapy, targeted therapy, bispecific antibody therapy, CAR-T therapy, and multiple cutting-edge clinical trials. Although each treatment initially yielded rapid results and effectively controlled the disease, drug resistance would quickly develop, leading to repeated relapses and preventing a permanent cure.
The long-term, repetitive treatments and the progression of the disease took a heavy toll on Mr. Yang’s physical health. Following a viral infection, the tumor metastasized to his lungs, marking the most difficult phase of his battle against the illness. He suffered from recurrent pulmonary infections and persistent high fevers, experiencing bouts of pneumonia every month; the long-term use of immunosuppressants further compromised his immune system, creating a vicious cycle that made the lung infections difficult to cure.
At one point during his treatment, a severe bacterial infection triggered critical pneumonia. His condition became life-threatening—to the extent that the local hospital issued a critical illness notice—and his condition was stabilized only after emergency intervention. He was subsequently transferred to the ICU due to a severe pulmonary infection; after nearly a month of shuttling between the ICU and general wards, he finally moved past the critical stage.
Despite recurring illness and the physical torment caused by the disease, Mr. Yang maintained a positive mindset. He persisted with moderate exercise and lifestyle adjustments, calmly coexisting with the illness while never abandoning hope for recovery.
03 Referral to Gaobo Hospital: Precision Care Breaks the Treatment Impasse
Prolonged recurrence and the continued progression of his pulmonary tumor caused Mr. Yang to suffer from persistent, violent coughing; he was unable to wean off high-flow oxygen therapy and was physically extremely frail. With no breakthroughs achieved through conventional treatments, a leading hematology expert recommended he visit Beijing Gaobo Hospital. The goal was to seek a personalized treatment plan by leveraging the hospital’s research-driven clinical capabilities and the department’s extensive experience in treating relapsed and refractory lymphoma.
Mr. Yang consulted Director Ke Xiaoyan at the Department of Lymphoma and Myeloma at Beijing Gaobo Hospital. The medical team conducted a detailed review of his medical records, treatment history, and the progression of his condition over the years. Given the complexity of his case—characterized by severe progression of pulmonary lesions, multidrug resistance, and recurrent infections—the expert team identified shortcomings in his previous treatments, specifically a lack of variety and a failure to implement a systematic, comprehensive approach. Despite the critical nature of his condition and the extensive invasion of the pulmonary lesions, the team decided to admit him and formulate a personalized rescue treatment plan.
Upon admission, Director Hu Kai’s team conducted a comprehensive review of the patient’s entire treatment history and physiological indicators. By meticulously organizing medical records and precisely assessing the condition, they rapidly finalized a brand-new, comprehensive treatment plan. Within just one week of standardized treatment, positive results emerged: the patient’s lung function improved significantly, he successfully weaned off the high-flow oxygen support he had long relied upon, and his overall physical condition began to recover.
During the subsequent course of treatment, as the patient faced recurring adverse reactions—such as infections and fevers—and fluctuations in his condition, Director Hu Kai’s team dynamically adjusted the treatment plan, precisely managed various complications, and maintained careful control over the pace of therapy. Under the team’s systematic treatment plan, Mr. Yang’s physical functions gradually recovered and his stamina steadily improved. He progressed from taking independent walks and covering long distances to eventually resuming sports like tennis, successfully shaking off the frailty and confinement to bed that had plagued him for years, and regaining control over his physical well-being.
04 Enrolling in a cutting-edge CAR-T clinical trial to achieve complete tumor remission
After chemotherapy stabilized his condition and improved his baseline physical health, a follow-up biopsy revealed that the patient was positive for the CD79b target. Leveraging the hospital’s strengths in cutting-edge clinical research, Mr. Yang successfully enrolled in the department’s clinical trial for CD79b CAR-T cell therapy, marking a major breakthrough in his treatment.
Following the CAR-T cell infusion, the patient experienced only a transient Grade 1 CRS (Cytokine Release Syndrome) reaction accompanied by a brief fever; the overall treatment process remained safe and manageable, with robust cell expansion. A follow-up assessment one month later showed partial remission (PR). After three months of continued treatment and follow-up, a whole-body PET/CT scan revealed the complete disappearance of all tumor lesions, signifying a successful achievement of complete remission (CR).
This marked the first time in his nine-year battle against the disease that Mr. Yang achieved the total clearance of systemic lesions, with imaging results showing the best status seen in years.
05 Reflections on a nine-year battle: Embracing the light, honoring the care received and the original resolve
After nine years of battling the disease and repeatedly overcoming dire situations, Mr. Yang’s successful outcome is a testament to the precision diagnosis, comprehensive management, and unwavering persistence of the Lymphoma and Myeloma team at Beijing Gaobo Hospital. Facing a complex case characterized by multidrug resistance, a complicated clinical picture, and severe complications, the team utilized their extensive clinical experience, systematic diagnostic approach, and cutting-edge technologies to transcend the limitations of traditional treatments, ultimately securing a chance for clinical cure.
His long journey fighting the disease taught Mr. Yang a profound lesson: mindset is just as important as medical treatment. There is no need to be overly anxious about fluctuating test markers or to let the illness dictate one’s life; actively adhering to standardized treatment and maintaining a healthy lifestyle are the keys to successfully fighting the tumor. Having recovered and been discharged, Mr. Yang now strictly follows medical advice regarding rest and follow-ups, maintains a regular daily routine, exercises consistently, and cultivates personal interests. By balancing his daily life with his ongoing recovery, he has truly realized the goal of “undergoing treatment for a better life.”
The patient’s rebirth also owes much to the quiet, steadfast support of his family. Over the years, they have shouldered the burdens of the household—caring for the elderly and raising the children—shielding him from the trivialities of daily life and providing a solid foundation of support. Their companionship and unwavering dedication gave him the strength to battle his illness, helping him endure countless hardships while never losing hope for life.
After a nine-year ordeal, Mr. Yang has finally overcome recurrent tumors and reclaimed a healthy life. This long journey against cancer stands not only as a vivid testament to the power of medical technology in conquering complex tumors but also as a profound embodiment of perseverance, passion, and the meaning of steadfast support.
Leave a reply